Idelalisib as a Bridge to Allogeneic Transplantation in Relapsed/Refractory Lymphoma With Renal Cancer: A Case Report

Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e15-e17. doi: 10.1016/j.clml.2019.10.008. Epub 2019 Oct 21.

Authors

Giulia Gabrielli¹, Alessandro Broccoli¹, Cinzia Pellegrini¹, Lisa Argnani¹, Michele Cavo¹, Pier Luigi Zinzani²

Affiliations

¹ Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy.
² Institute of Hematology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy. Electronic address: pierluigi.zinzani@unibo.it.

PMID: 31711891
DOI: 10.1016/j.clml.2019.10.008

No abstract available

Keywords: Allogeneic stem cell transplant; Follicular lymphoma; Idelalisib; Refractory; Relapsed.

Publication types

Case Reports

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use*
Hematopoietic Stem Cell Transplantation / methods*
Humans
Kidney Neoplasms / drug therapy*
Lymphoma / complications
Lymphoma / drug therapy*
Male
Middle Aged
Purines / pharmacology
Purines / therapeutic use*
Quinazolinones / pharmacology
Quinazolinones / therapeutic use*
Transplantation Conditioning / methods*
Transplantation, Homologous / methods*

Substances

Antineoplastic Agents
Purines
Quinazolinones
idelalisib